Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Immunome Inc (NQ: IMNM )

12.09 -0.21 (-1.71%)
Streaming Delayed Price Updated: 10:57 AM EDT, Oct 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Immunome Inc

< Previous 1 2 3 Next >
Immunome’s Antibody Cocktail Effective Against SARS-CoV-2 Omicron Variant in In Vitro Live Virus Testing
From Immunome, Inc.
Via Business Wire
Immunome Provides Update on Investigational New Drug Application for IMM-BCP-01 for the Treatment of COVID-19
From Immunome, Inc.
Via Business Wire
Immunome to Participate in Fireside Chat Hosted by Cantor Fitzgerald
From Immunome, Inc.
Via Business Wire
Immunome Expects IMM-BCP-01 Antibody Cocktail To Neutralize the SARS-CoV-2 Omicron Variant
From Immunome, Inc.
Via Business Wire
Immunome Announces Submission of an Investigational New Drug (IND) Application for IMM-BCP-01 for the Treatment of COVID-19
From Immunome, Inc.
Via Business Wire
Immunome Reports Third Quarter 2021 Financial Results
From Immunome, Inc.
Via Business Wire
Immunome to Present at the Stifel Healthcare Conference
From Immunome, Inc.
Via Business Wire
Immunome Announces Submission for Publication of Pre-clinical Research Detailing the Importance of Antibody Cocktail for SARS-CoV-2 Treatment and Prophylaxis
From Immunome, Inc.
Via Business Wire
Immunome Presents Compelling Preclinical Data on Anti-IL-38 Antibody Program at the American Association for Cancer Research NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Immunome, Inc.
Via Business Wire
Immunome to Present Preclinical Data on Anti IL-38 Antibody Program at the American Association for Cancer Research NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Immunome, Inc.
Via Business Wire
Immunome to Present at the Cantor Global Healthcare Conference
From Immunome, Inc.
Via Business Wire
Immunome to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
From Immunome, Inc.
Via Business Wire
Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes SARS-CoV-2 Lambda and Delta Plus Variants in Pre-clinical Testing
From Immunome, Inc.
Via Business Wire
Immunome Reports Second Quarter 2021 Financial Results
From Immunome, Inc.
Via Business Wire
Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes the SARS-CoV-2 Delta Variant in Pre-clinical Testing
From Immunome, Inc.
Via Business Wire
Immunome to Present at the Ladenburg Thalmann 2021 Healthcare Conference
From Immunome, Inc.
Via Business Wire
Immunome Appoints Andrew Badley, M.D., to COVID-19 Advisory Board
From Immunome, Inc.
Via Business Wire
Immunome Appoints Franklyn G. Prendergast, M.D., Ph.D., to Board of Directors
From Immunome, Inc.
Via Business Wire
Immunome to Present at the Jefferies Virtual Healthcare Conference
From Immunome, Inc.
Via Business Wire
Immunome Announces Additional $4.3 Million Award by DOD following Positive Preclinical Testing Results on COVID-19 Variants of Concern
From Immunome, Inc.
Via Business Wire
Immunome Reports First Quarter 2021 Financial Results
From Immunome, Inc.
Via Business Wire
Immunome SARS-CoV-2 Antibody Cocktail Neutralizes UK, South Africa, Brazil and California Variants in Preclinical Testing; Progressing Towards IND Filing
From Immunome, Inc.
Via Business Wire
Immunome Announces $27 Million Private Placement
From Immunome, Inc.
Via Business Wire
Immunome Appoints Corleen Roche as Chief Financial Officer
From Immunome
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.